Share

Clinical Studies (1)

  • Leppert : Study aims to evaluate the efficacy and safety of Temelimab as a treatment for post COVID-19 syndrome neuropsychiatric symptoms in patients who had severe acute SARS-CoV-2 infection but did not undergo intensive care treatment during the acute period

Study Data

  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition
  • Pharmacological intervention
  • Monoclonal antibodies
  • Temelimab

Other information

If you would like to contact the site, please email: ccb@ateneo.univr.it

The data is updated up to